Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juliana Eng

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
JCO Precision Oncology|June 29, 2023
Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced <i>KRAS G12C</i>-Mutant Non-Small Cell Lung CancerRohit Thummalapalli, Ezra Bernstein, Benjamin Herzberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2020
A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung CancersPaul K Paik, Rachel K Kim, Linda Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2020
Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell CarcinomaSean McBride, Eric Sherman, C Jillian Tsai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2024
A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung CancerNoura J Choudhury, W Victoria Lai, Alex Makhnin, et al.
JTO Clinical and Research Reports|April 6, 2026
Brain Metastases in Diffuse Pleural Mesothelioma: Clinical, Histologic, and Molecular CorrelatesAntonio Ocejo, Clare Wilhem, Francis M Bodd, et al.
Lancet (London, England)|December 17, 2023
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 studyChiaojung Jillian Tsai, Jonathan T Yang, Narek Shaverdian, et al.
International Journal of Radiation Oncology, Biology, Physics|March 8, 2023
Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation PneumonitisAndreas Rimner, Zachary R Moore, Stephanie Lobaugh, et al.
Nature Medicine|August 24, 2023
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trialJoris L Vos, Bharat Burman, Swati Jain, et al.
Cancer Immunology Research|December 18, 2023
Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota TransplantationArielle Elkrief, Nicholas R Waters, Natalie Smith, et al.
International Journal of Cancer|February 15, 2021
Any day, split halfway: Flexibility in scheduling high-dose cisplatin-A large retrospective review from a high-volume cancer centerJung Julie Kang, Vatche Tchekmedyian, Nader Mohammed, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
JCO Precision Oncology|June 29, 2023
Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced <i>KRAS G12C</i>-Mutant Non-Small Cell Lung CancerRohit Thummalapalli, Ezra Bernstein, Benjamin Herzberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2020
A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung CancersPaul K Paik, Rachel K Kim, Linda Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2020
Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell CarcinomaSean McBride, Eric Sherman, C Jillian Tsai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2024
A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung CancerNoura J Choudhury, W Victoria Lai, Alex Makhnin, et al.
JTO Clinical and Research Reports|April 6, 2026
Brain Metastases in Diffuse Pleural Mesothelioma: Clinical, Histologic, and Molecular CorrelatesAntonio Ocejo, Clare Wilhem, Francis M Bodd, et al.
Lancet (London, England)|December 17, 2023
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 studyChiaojung Jillian Tsai, Jonathan T Yang, Narek Shaverdian, et al.
International Journal of Radiation Oncology, Biology, Physics|March 8, 2023
Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation PneumonitisAndreas Rimner, Zachary R Moore, Stephanie Lobaugh, et al.
Nature Medicine|August 24, 2023
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trialJoris L Vos, Bharat Burman, Swati Jain, et al.
Cancer Immunology Research|December 18, 2023
Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota TransplantationArielle Elkrief, Nicholas R Waters, Natalie Smith, et al.
International Journal of Cancer|February 15, 2021
Any day, split halfway: Flexibility in scheduling high-dose cisplatin-A large retrospective review from a high-volume cancer centerJung Julie Kang, Vatche Tchekmedyian, Nader Mohammed, et al.
Pageof 3